Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (281-290 of 343) with videos related to

Pageof 35
Sort By:
The Journal of Rheumatology|February 16, 2022
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working GroupAnna Antony, Richard Holland, Ashish J Mathew, et al.
BMJ Open|September 28, 2023
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritisAlexander Ooms, Hussein Al-Mossawi, Louise Bennett, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Eclinicalmedicine|June 11, 2025
European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritisLeontios J Hadjileontiadis, Vasileios Charisis, Stelios Hadjidimitriou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 8, 2021
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal StudyLaura C Coates, Sreekumar G Pillai, Hasan Tahir, et al.
RMD Open|September 14, 2023
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional studyYing Ying Leung, Lihi Eder, Ana-Maria Orbai, et al.
Rheumatology (Oxford, England)|May 31, 2022
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDsLaura Tucker, Alexander Allen, David Chandler, et al.
Annals of the Rheumatic Diseases|June 19, 2025
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
Nature Communications|July 2, 2025
Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022Marta Pineda-Moncusí, Freya Allery, Hoda Abbasizanjani, et al.
Pageof 35

Showing results (281-290 of 343) with videos related to

Sort By:
Pageof 35
The Journal of Rheumatology|February 16, 2022
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working GroupAnna Antony, Richard Holland, Ashish J Mathew, et al.
BMJ Open|September 28, 2023
Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritisAlexander Ooms, Hussein Al-Mossawi, Louise Bennett, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Eclinicalmedicine|June 11, 2025
European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritisLeontios J Hadjileontiadis, Vasileios Charisis, Stelios Hadjidimitriou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 8, 2021
Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal StudyLaura C Coates, Sreekumar G Pillai, Hasan Tahir, et al.
RMD Open|September 14, 2023
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional studyYing Ying Leung, Lihi Eder, Ana-Maria Orbai, et al.
Rheumatology (Oxford, England)|May 31, 2022
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDsLaura Tucker, Alexander Allen, David Chandler, et al.
Annals of the Rheumatic Diseases|June 19, 2025
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
Nature Communications|July 2, 2025
Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022Marta Pineda-Moncusí, Freya Allery, Hoda Abbasizanjani, et al.
Pageof 35